Detalles de la búsqueda
1.
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Diabetes Obes Metab;
26(1): 191-200, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37814928
2.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Ann Intern Med;
176(12): 1606-1616, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048573
3.
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
Kidney Int;
103(1): 196-206, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36367466
4.
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Am J Nephrol;
54(9-10): 370-378, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37708857
5.
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
Diabetes Obes Metab;
25(2): 407-416, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36193847
6.
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
Diabetes Obes Metab;
25(6): 1512-1522, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36722675
7.
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
Diabetes Obes Metab;
25(10): 2989-2998, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402696
8.
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
J Am Soc Nephrol;
33(1): 225-237, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34732509
9.
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
Int J Mol Sci;
23(16)2022 Aug 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36012508
10.
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
Am Heart J;
222: 166-173, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32092505
11.
Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance.
Diabetes Care;
47(3): 362-370, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38151465
12.
Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population.
Clin Kidney J;
17(4): sfae052, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38650758
13.
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
JAMA Cardiol;
8(8): 732-741, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314801
14.
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
Clin Kidney J;
16(2): 293-302, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36864892
15.
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Diabetes Res Clin Pract;
204: 110908, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37805000
16.
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Clin J Am Soc Nephrol;
2023 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36927680
17.
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
Kidney Med;
5(10): 100704, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37745646
18.
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
Kidney Med;
5(12): 100730, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38046911
19.
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
JAMA Netw Open;
5(10): e2236123, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36287567
20.
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
JACC Heart Fail;
10(11): 860-870, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328655